Inventiva S.A. American Depositary Receipt (IVA)
Summary
IVA Chart
People also search for
Inventiva: Significant Upside Potential Ahead Of Pivotal Liver Disease Readout
Inventiva receives a speculative strong buy rating, with a probability-weighted fair value of ~$15 per share versus ~$3.20 currently. Following strong Phase 2b NATIVE results, lanifibranor's pivotal Phase 3 NATiV3 readout is imminent, creating a major potential catalyst for the stock. The model yields a 40% probability of a $29 fair value per share, versus a 32% probability of near-total loss, with intermediate valuations reflecting varying degrees of clinical differentiation.
Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test
Inventiva NASDAQ: IVA said it expects to report top-line results in the fourth quarter of 2026 from its fully enrolled Phase III NATiV3 trial of lanifibranor in patients with metabolic dysfunction-associated steatohepatitis, or MASH.
Inventiva S.A. (IVA) Q2 2026 Earnings Call Transcript
Inventiva S.A. (IVA) Q2 2026 Earnings Call Transcript
Inventiva S.A. American Depositary Receipt Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 83,996 | $298,185.8 | $296,085.9 | -$2,099.9 | -0.7% |
 Point72 Asset Management LP Point72 Asset Management LP | 1.68M | $7.89M | $6M | -$1.89M | -23.93% |
 David Kim Paradigm Biocapital Advisors LP | 4M | $18.6M | $14.96M | -$3.64M | -19.57% |
| NM Nir Messafi Deep Track Capita LLP | 800,000 | $4.38M | $3.03M | -$1.35M | -30.76% |
 Peter Platt Platt Investment Counsel LLC | 12,260 | $45,239.4 | $45,178.1 | -$61.3 | -0.14% |
Inventiva S.A. American Depositary Receipt (IVA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Inventiva S.A. American Depositary Receipt ever had a stock split?
Inventiva S.A. American Depositary Receipt Profile
| Biotechnology Industry | Healthcare Sector | Andrew Obenshain CEO | NASDAQ (NMS) Exchange | 46124U107 CUSIP |
| FR Country | 77 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Inventiva S.A. is a trailblazer in the biopharmaceutical field, primarily engaged in discovering and developing oral small molecule therapies. Established in 2011, and operating from its headquarters in Daix, France, the company has positioned itself at the forefront of tackling complex diseases, with an emphasis on non-alcoholic steatohepatitis (NASH) and a variety of other significant diseases. Venturing beyond the traditional boundaries of medicine, Inventiva is committed to innovating solutions that have the potential to reshape treatments and improve patient outcomes significantly.
Products and Services
- Lanifibranor
Inventiva's flagship product, Lanifibranor, is an oral small molecule therapy currently undergoing a Phase III clinical trial aimed at treating non-alcoholic steatohepatitis (NASH), a liver disease with limited current treatment options. This therapeutic candidate stands out for its ability to address a critical unmet need in the healthcare sector, offering hope to patients suffering from this progressively worsening condition.
- Odiparcil
Another innovative product in Inventiva’s portfolio is Odiparcil, a therapy that has completed Phase IIa clinical trials and is designed to treat mucopolysaccharidoses type VI disease. This rare and serious condition affects the body's ability to break down large molecules, leading to severe symptoms that impact the quality of life. Odiparcil represents Inventiva’s commitment to addressing rare diseases with high unmet medical needs, showcasing the company's dedication to extending its research and development capabilities beyond its primary focus areas.
Beyond these leading product candidates, Inventiva continues to expand its horizon with a pipeline that encompasses earlier-stage programs targeting oncology and several other diseases. This approach exemplifies the company's strategic vision towards diversification and innovation, aiming to leverage its expertise in drug development to contribute significantly across a broad spectrum of healthcare challenges.
Contact Information
